MBX Biosciences, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MBX Nasdaq 2830 mbxbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MBX Biosciences, Inc.

MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights - Aug 6th, 2026 6:00 am
Stock Market Checklist Helps Uncover Winners In Hot Biotechs - Jul 31st, 2026 9:09 am
Attovia Therapeutics Appoints John W. Smither to Board of Directors - Jul 15th, 2026 6:30 am
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth - Jul 13th, 2026 2:15 pm
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Jul 7th, 2026 8:31 am
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Jun 15th, 2026 2:14 pm
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) - Jun 12th, 2026 6:52 am
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - Jun 12th, 2026 5:00 am
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch - Jun 11th, 2026 3:27 am
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - Jun 1st, 2026 6:00 am
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - May 27th, 2026 1:38 pm
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - May 26th, 2026 6:00 am
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - May 15th, 2026 7:18 am
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push - May 11th, 2026 1:09 pm
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - May 11th, 2026 5:00 am
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights - May 7th, 2026 6:00 am
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award - May 7th, 2026 5:00 am
3 Overlooked Stocks Set to Soar in 2026 - May 5th, 2026 7:05 am
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - Apr 23rd, 2026 6:00 am
Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase - Apr 22nd, 2026 9:00 am